{"doi":"10.1111/acer.14768","title":"Naltrexone moderates the association of alcohol use and affect among adolescent drinkers in daily life","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Naltrexone is an efficacious medication for the treatment of alcohol use disorder in adults. As an opioid receptor antagonist, naltrexone blocks activation of the endogenous opioid system, which is involved in the affectively reinforcing properties of substance use. Few studies, however, have examined the moderating effect of naltrexone on the association between affect and alcohol use. Additionally, most existing research on naltrexone has been with adults in the human laboratory.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>We conducted a secondary analysis of ecological momentary assessment data from a randomized, double‐blinded, placebo‐controlled cross‐over study that compared naltrexone (50 mg/daily) and placebo in 26 adolescents (15 to 19 years old) who exhibited problematic drinking patterns. Multilevel models tested whether naltrexone moderated associations of alcohol use with both positive and negative affect (PA, NA).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Results indicated that, during naltrexone treatment, greater estimated blood alcohol concentration (eBAC) levels were associated with greater NA further into drinking episodes. In turn, greater NA after the first drink of an episode was associated with reduced subsequent eBAC values during naltrexone treatment. Low PA was also associated with lower subsequent eBAC levels in the naltrexone condition after the first drink.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>These findings support the idea that naltrexone can disrupt the association between affect and alcohol use, effects that emerge later in drinking episodes. Greater attention to the effects of naltrexone on affect and reinforcement may help to tailor psychotherapy to maximize the benefits of naltrexone. However, in the present study, as most drink reports were in the first 2 h of the drinking episode and participants reported affect only at the first three end‐drink reports of a drinking episode (limiting the number of drinks reported), we had reduced power to detect effects in the continuation phase. Thus, replication of the findings is needed using a design that assesses the impact of naltrexone across the entire episode.</jats:p></jats:sec>","journal":"Alcoholism: Clinical and Experimental Research","year":2022,"id":29503,"datarank":0.3794808283392746,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.06756459708729919,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.06756459708729919,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":7,"citers_with_citation_signal":5,"citers_with_endowment":5,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":162547,"name":"Noah N. Emery","orcid":"0000-0002-4891-2303","position":1,"is_corresponding":false},{"id":162548,"name":"Samuel N. Meisel","orcid":"0000-0003-2298-3653","position":2,"is_corresponding":false},{"id":162549,"name":"Robert Miranda","orcid":"0000-0001-6418-6148","position":3,"is_corresponding":false},{"id":162546,"name":"Ryan W. Carpenter","orcid":"0000-0002-1351-7071","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34959253","pmcid":"PMC8858857","openalex_id":"https://openalex.org/W4200613687","authors":[],"funders":[{"funder_name":"National Institute on Drug Abuse","grant_id":"DA016184","title":null},{"funder_name":"National Institute on Alcohol Abuse and Alcoholism","grant_id":"AA017273","title":null},{"funder_name":"National Institute on Alcohol Abuse and Alcoholism","grant_id":"AA026326","title":null},{"funder_name":"National Institute on Alcohol Abuse and Alcoholism","grant_id":"AA028414","title":null},{"funder_name":"National Institute on Alcohol Abuse and Alcoholism","grant_id":"AA07459","title":null},{"funder_name":"NIAAA NIH HHS","grant_id":"F32 AA028414","title":null},{"funder_name":"NIAAA NIH HHS","grant_id":"K24 AA026326","title":null},{"funder_name":"NIAAA NIH HHS","grant_id":"T32 AA007459","title":null},{"funder_name":"NIAAA NIH HHS","grant_id":"R21 AA017273","title":null},{"funder_name":"NIDA NIH HHS","grant_id":"T32 DA016184","title":null},{"funder_name":"National Institutes of Health","grant_id":"1F32AA028414-01","title":"Leveraging Ecological Momentary Assessment to Examine Peer Affiliations as a Mechanism of Behavior Change in Youth Alcohol Use Treatment"},{"funder_name":"National Institutes of Health","grant_id":"2K24AA026326-06","title":"Mentored Patient-Oriented Research on Adolescent Alcohol Misuse and Treatment"},{"funder_name":"National Institutes of Health","grant_id":"5T32AA007459-32","title":"Alcohol Intervention Treatment Outcome Research Training"},{"funder_name":"National Institutes of Health","grant_id":"5R21AA017273-02","title":"Mechanisms of Naltrexone Action on Drinking in Adolescents"}],"total_grants":14,"fwci":0.6106,"citation_percentile":0.70012421,"influential_citations":0,"citation_trend":[{"year":2022,"count":1},{"year":2023,"count":1},{"year":2024,"count":2},{"year":2025,"count":3}],"oa_status":"green","license":"Wiley Online Library User Agreement","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8858857","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858857","host_type":"GREEN"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8858857","host_type":"repository"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/acer.14768","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/acer.14768","host_type":"publisher"},{"url":"https://doi.org/10.1111/acer.14768","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34959253","host_type":"repository"}],"fields_of_study":["Substance Abuse Treatment and Outcomes","Neurotransmitter Receptor Influence on Behavior","Alcohol Consumption and Health Effects","Medicine","Psychology","03 medical and health sciences","0302 clinical medicine","Adolescent","Alcohol Deterrents","Alcoholism","Cross-Over Studies","Double-Blind Method","Female","Humans","Male","Naltrexone","Underage Drinking"],"mesh_terms":["Underage Drinking","Adolescent","Alcohol Deterrents","Alcoholism","Double-Blind Method","Female","Humans","Male","Naltrexone","Cross-Over Studies"],"keywords":["Naltrexone","Opioid antagonist","Affect (linguistics)","Placebo","Narcotic antagonist","Alcohol dependence","Psychology","Alcohol","Opioid","Endogenous opioid","Psychiatry","Clinical psychology","Medicine","Internal medicine","Chemistry","(+)-Naloxone","Receptor","Reinforcement","Adolescents","Alcohol Use Disorder","Ecological Momentary Assessment","Male","Alcoholism","Cross-Over Studies","Adolescent","Double-Blind Method","Humans","Female","Underage Drinking","Alcohol Deterrents"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-09T00:01:39.110815Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}